Structural basis of alpha-fucosidase inhibition by iminocyclitols with K(i) values in the micro- to picomolar range.

of 10 for human a-fucosidase is0.40 nm.[*] Dr. H.-J. Wu, C.-W. Ho, Dr. T.-P. Ko, Dr. S. D. Popat, Prof. C.-H. Lin,Prof. A. H.-J. WangInstitute of Biological Chemistry, CBMB, Taiwan InternationalGraduate Program, Academia Sinica128 Section 2, Academia Road, Nankang, Taipei 11529 (Taiwan)Fax: ( +886)2-2788-9759E-mail: chunhung@gate.sinica.edu.twahjwang@gate.sinica.edu.twC.-W. HoDepartment of Chemistry, National Tsing-Hua UniversityTaipei (Taiwan)[**] This work was supported by Academia Sinica and the NationalScience Council (95-3112-B-001-015). We thank NSRRC of Taiwan,SPring-8 of Japan, and ALS of USA for beam time allocations. H.-J. W. is grateful for an NHMRC C. J. Martin Fellowship fromAustralia.Supporting information for this article is available on the WWWunder http://dx.doi.org/10.1002/anie.200905597.

[1]  Spencer J. Williams,et al.  Atomic resolution analyses of the binding of xylobiose-derived deoxynojirimycin and isofagomine to xylanase Xyn10A. , 2004, Chemical communications.

[2]  T. Dafforn,et al.  Comprehensive biological catalysis , 1998 .

[3]  G. Evans,et al.  Altered enthalpy-entropy compensation in picomolar transition state analogues of human purine nucleoside phosphorylase. , 2009, Biochemistry.

[4]  M. Du,et al.  Serum and tissue alpha-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma. , 1991, Clinical science.

[5]  David R. Rose,et al.  Detailed structural analysis of glycosidase/inhibitor interactions: complexes of Cex from Cellulomonas fimi with xylobiose-derived aza-sugars. , 2000, Biochemistry.

[6]  J. Darby,et al.  Fucosidosis revisited: a review of 77 patients. , 1991, American journal of medical genetics.

[7]  Jung-Hsin Lin,et al.  Restrained molecular dynamics simulations of HIV‐1 protease: The first step in validating a new target for drug design , 2006, Biopolymers.

[8]  A. Vasella,et al.  Structural, kinetic, and thermodynamic analysis of glucoimidazole-derived glycosidase inhibitors. , 2006, Biochemistry.

[9]  S. Raptis,et al.  Long‐term effectiveness of a new α‐glucosidase inhibitor (BAY m1099‐miglitol) in insulin‐treated Type 2 diabetes mellitus , 1998 .

[10]  Chi‐Huey Wong,et al.  Discovery of picomolar slow tight-binding inhibitors of alpha-fucosidase. , 2004, Chemistry & biology.

[11]  M. Páez de la Cadena,et al.  Value of the Serum Alpha-L-Fucosidase Activity in the Diagnosis of Colorectal Cancer , 2000, Oncology.

[12]  David L Zechel,et al.  Direct observation of the protonation state of an imino sugar glycosidase inhibitor upon binding. , 2003, Journal of the American Chemical Society.

[13]  Y. Liu,et al.  3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. , 2004, Biochemistry.

[14]  J. Gordon,et al.  Glycans as legislators of host-microbial interactions: spanning the spectrum from symbiosis to pathogenicity. , 2001, Glycobiology.

[15]  David Zechel,et al.  Glycosidase inhibition: an assessment of the binding of 18 putative transition-state mimics. , 2007, Journal of the American Chemical Society.

[16]  G. Evans,et al.  Femtomolar Transition State Analogue Inhibitors of 5′-Methylthioadenosine/S-Adenosylhomocysteine Nucleosidase from Escherichia coli* , 2005, Journal of Biological Chemistry.

[17]  Young-Wan Kim,et al.  Expanding the thioglycoligase strategy to the synthesis of alpha-linked thioglycosides allows structural investigation of the parent enzyme/substrate complex. , 2006, Journal of the American Chemical Society.

[18]  Yi-Ting Wang,et al.  Role for α-l-fucosidase in the control of Helicobacter pylori-infected gastric cancer cells , 2009, Proceedings of the National Academy of Sciences.

[19]  V. Schramm,et al.  Transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases. , 2009, Journal of the American Chemical Society.

[20]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  W. Jencks,et al.  Binding energy, specificity, and enzymic catalysis: the circe effect. , 2006, Advances in enzymology and related areas of molecular biology.

[22]  N. Asano.  Glycosidase inhibitors: update and perspectives on practical use. , 2003, Glycobiology.

[23]  S. Withers,et al.  Structural analysis of Golgi alpha-mannosidase II inhibitors identified from a focused glycosidase inhibitor screen. , 2008, Biochemistry.

[24]  Ad Bax,et al.  Flexibility and function in HIV-1 protease , 1995, Nature Structural Biology.

[25]  S. Withers,et al.  Crystal structure of Thermotoga maritima alpha-L-fucosidase. Insights into the catalytic mechanism and the molecular basis for fucosidosis. , 2004, The Journal of biological chemistry.

[26]  S. Withers,et al.  The structural basis of glycosidase inhibition by five-membered iminocyclitols: the clan a glycoside hydrolase endoglycoceramidase as a model system. , 2007, Angewandte Chemie.

[27]  Chung-Yi Wu,et al.  Discovery of different types of inhibition between the human and thermotoga maritima alpha-fucosidases by fuconojirimycin-based derivatives. , 2006, Biochemistry.

[28]  Xiaowu Chen,et al.  Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. , 2000, Current medicinal chemistry.

[29]  I. Jelesarov,et al.  Thermodynamic characterization of ligand-induced conformational changes in UDP-N-acetylglucosamine enolpyruvyl transferase. , 2001, Biochemistry.

[30]  M. Glick,et al.  Activity of fucosyltransferases and altered glycosylation in cystic fibrosis airway epithelial cells. , 2001, Biochimie.